Review article: The safety profile of tegaserod

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 7, 2004, Pages 25-30

  Schoenfeld, P ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CISAPRIDE; ORAL CONTRACEPTIVE AGENT; PLACEBO; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; TEGASEROD; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ABDOMINAL SURGERY; ATRIOVENTRICULAR BLOCK; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART PALPITATION; HUMAN; INCIDENCE; INTESTINE ISCHEMIA; IRRITABLE COLON; ISCHEMIC COLITIS; NAUSEA; PELVIS SURGERY; PRIORITY JOURNAL; QT PROLONGATION; SPONTANEOUS ABORTION; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; TORSADE DES POINTES;

EID: 10644288497     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02182.x     Document Type: Conference Paper

References (25)

1. 4 agonist for women with constipation-predominant irritable bowel syndrome. Hosp Formulary 2002; 37: 449.
2. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51.
3. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
4. 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577-86.
5. Schoenfeld P, Chey WD, Drossman D, et al. Effectiveness and safety of tegaserod in treatment of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Gastroenterology 2002; 122: A1486(Abstract).
6. 4 partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
7. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
8. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-76.
9. Cohen Munoz V. Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (IBS-C) (Abstract). Gastroenterology 2003; 124: T1804.
10. Lin S, Zhou L, Xinguang L, et al. Tegaserod provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in Chinese patients with irritable bowel syndrome with constipation (Abstract). Gastroenterology 2003; 124: S1017.
11. Nyhlin H, Bang C, Elsborg L, et al. Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population. Gastroenterology 2003; 124: M1645.
12. Wald A, Johanson J, Tougas G, et al. Safety and tolerability of tegaserod in patients treated for chronic constipation (CC): a 12-week, double-blind, placebo-controlled multicenter study performed in the Americas. Gastroenterology 2003; 124: T1818.
13. Hugot S, Fordham F. Study E2301. A randomized, double-blind, placebo-controlled multicenter study to assess the efficacy, safety and tolerability of tegaserod 2 mg bid and 6 mg bid given orally vs. placebo in patients with chronic constipation. Novartis Pharmaceuticals Corporation. 2002. Data on file.
14. Tougas G, Snape WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1701-8.
15. Clinical development - Tegaserod. Integrated summary of safety - Update. Novartis Pharmaceuticals Corporation, 2000. Data on file.
16. Clinical development - Tegaserod. Integrated summary of safety - Update. Novartis Pharmaceuticals Corporation. 2002. Data on file.
17. Earnest D, Ruegg ED, Dunger-Baldauf C, Lefkowitz M. Diarrhea in patients treated with tegaserod for irritable bowel syndrome with constipation (IBS-C) is infrequent and usually self-limited. Am J Gastroenterol 2002; 97: A843(Abstract).
18. Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol 2002; 97: 1176-81.
19. Schoenfeld P. Systematic review: incidence of abdominal-pelvic surgery among patients using tegaserod in randomized controlled trials. Aliment Pharmacol Ther 2004; 19: 263-9.
20. Bran S, Murray WA, Hirsch IB, et al. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 765-8.
21. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34: 82-8.
22. Morganroth J, Ruegg PC, Dunger-Baldauf C, et al. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97: 2321-7.
23. Higgins PDR, Davis KJ, Laine L. Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 2004; 19: 729-38.
24. Singh G, Mithal A, Triadafilopoulos G. Patients with irritable bowel syndrome have a high-risk of developing ischemic colitis. Gastroenterology 2004; 126: A349(Abstract).
25. Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 partial agonist with promotile activity. Clin Pharmacokinet 2002; 41: 1021-42.